Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase

Antiviral Therapy

Volumn 17, Issue 3, 2012, Pages 411-423

  Pawlotsky, Jean Michel ^a,b   Najera, Isabel ^c   Jacobson, Ira ^d  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

^c HOFFMANN LA ROCHE INC   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 2' FLUORO 2' METHYLCYTIDINE; ALISPORIVIR; ASUNAPREVIR; DACLATASVIR; DANOPREVIR; GS 9256; MERICITABINE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED RNA POLYMERASE; RNA DIRECTED RNA POLYMERASE INHIBITOR; SERINE; TEGOBUVIR; THREONINE; UNCLASSIFIED DRUG; VALOPICITABINE; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; LOW DRUG DOSE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEQUENCE ANALYSIS; TREATMENT DURATION; VIRUS REPLICATION; WILD TYPE;

ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; RNA REPLICASE; TREATMENT OUTCOME;

EID: 84861655785     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2088     Document Type: Review

References (62)

1. US Food and Drug Administration. Approval of Incivek (telaprevir), a direct acting antiviral drug (DAA) to treat hepatitis C (HCV). (Updated 25 May 2011. Accessed 15 February 2012.) Available from http://www.fda.gov/ ForConsumers/ByAudience/ForPatientAdvocates/ucm256328.htm
2. US Food and Drug Administration. Approval of Victrelis (boceprevir) a direct acting antiviral drug (DAA) to treat hepatitis C virus (HCV). (Updated 25 May 2011. Accessed 15 February 2012.) Available from http://www.fda.gov/ ForConsumers/ByAudience/ForPatientAdvocates/ucm255413.htm
3. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-1838.
4. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.
5. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatmentnaive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet 2010; 376:705-716.
6. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362:1292-1303.
7. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
8. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
9. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
10. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
11. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132:1767-1777. (Pubitemid 46677938)
12. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132:1270-1278. (Pubitemid 46627577)
13. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46:631-639. (Pubitemid 47436107)
14. Chevaliez S, Rodriguez A, Soulier A, Ahmed-Belkacem A, Hézode C, Pawlotsky J-M. Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations. J Hepatol 2011; 54 Suppl 1:S30.
15. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53:1742-1751.
16. Incivek (telaprevir). Package insert 2011. Vertex Pharmaceuticals, Inc., Cambridge, MA, USA.
17. Victrelis (Boceprevir). Package insert 2011. Schering Corporation, a subsidiary of Merck and Co., Whitehouse Station, NJ, USA.
18. Zeuzem S, Sulkowski M, Zoulim F, et al. Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study. Hepatology 2010; 52 Suppl 1:436A.
19. Sullivan J, De Meyer S, Bartels D, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. J Hepatol 2011; 54 Suppl 1:S4.
20. Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol 2011; 54:566-576.
21. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. An overview of HCV molecular biology, replication and immune responses. Virol J 2011; 8:161.
22. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132:1979-1998. (Pubitemid 46695724)
23. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55:192-206.
24. Vermehren J, Sarrazin C. New HCV therapies on the horizon. Clin Microbiol Infect 2011; 17:122-134.
25. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131:997-1002. (Pubitemid 44498690)
26. Le Pogam S, Yan J, Chhabra M, et al. Low prevalence of danoprevir resistance identified in genotype 1b HCV patients with prior null response treated with danoprevir plus low-dose ritonavir plus peginterferon alfa-2a (40KD)/ribavirin for 12 weeks. J Hepatol 2011; 54 Suppl 1:S485.
27. McCown MF, Rajyaguru S, Kular S, Cammack N, Najera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009; 53:2129-2132.
28. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138:447-462.
29. Wagner F, Thompson R, Kantaridis C, et al. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology 2011; 54:50-59.
30. Lok A, Gardiner D, Lawitz E, et al. Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. J Hepatol 2011; 54 Suppl 1:S536.
31. Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PEGIFN/RBV for up to 28 days in treatment naive genotype 1 HCV subjects. Hepatology 2010; 52 Suppl 1:400A.
32. Coelmont L, Hanoulle X, Chatterji U, et al. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS ONE 2010; 5:e13687.
33. Puyang X, Poulin DL, Mathy JE, et al. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. Antimicrob Agents Chemother 2010; 54:1981-1987.
34. McCown MF, Rajyaguru S, Le Pogam S, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008; 52:1604-1612. (Pubitemid 351614649)
35. Lam AM, Espiritu C, Bansal S, et al. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations with replicon RNA. J Virol 2011; 85:12334-12342.
36. Lawitz E, Rodriguez-Torres M, Denning J, et al. Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA < LOD at day 14: first purine/pyrimidine clinical combination data (the NUCLEAR study). J Hepatol 2011; 54 Suppl 1:S543.
37. Ma H, Jiang WR, Robledo N, et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2′- fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species. J Biol Chem 2007; 282:29812-29820. (Pubitemid 350035263)
38. Murakami E, Bao H, Ramesh M, et al. Mechanism of activation of beta- D-2′-deoxy-2′-fluoro-2′-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother 2007; 51:503-509. (Pubitemid 46185267)
39. Murakami E, Niu C, Bao H, et al. The mechanism of action of beta- D-2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to beta- D-2′-deoxy-2′-fluoro-2′-C- methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2008; 52:458-464. (Pubitemid 351170814)
40. Leveque V, Fung A, Le Pogam S, et al. Nucleoside analog R7128, a prodrug of PSI-6130, shows inhibition potency across HCV genotypes 1-6 in vitro. 16th International Symposium on Hepatitis C Virus and Related Viruses. 3-7 October 2009, Nice, France. Poster P-215.
41. Ali S, Leveque V, Le Pogam S, et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack crossresistance with R1479. Antimicrob Agents Chemother 2008; 52:4356-4369.
42. Migliaccio G, Tomassini JE, Carroll SS, et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 2003; 278:49164-49170.
43. Olsen DB, Eldrup AB, Bartholomew L, et al. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother 2004; 48:3944-3953. (Pubitemid 39304626)
44. Le Pogam S, Jiang WR, Leveque V, et al. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methylcytidine or to R1479 show lack of cross resistance. Virology 2006; 351:349-359. (Pubitemid 44108072)
45. Reddy R, Rodriguez-Torres M, Gane E, et al. Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 2007; 46 Suppl 1:862A-863A.
46. Gane E, Rodriguez-Torres M, Nelson D, et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500mg BID with PEG-IFN and ribavirin for 28 days. Hepatology 2008; 48 Suppl 1:1024A.
47. Rodriguez-Torres M, Lalezari J, Gane E, et al. Potent antiviral response to the HCV nucleoside polymerase inhibitor R7128 for 28 days with PEG-IFN and ribavirin: subanalysis by race/ethnicity, weight and HCV genotype. Hepatology 2008; 48 Suppl 1:1160A.
48. Jensen D, Wedemeyer H, Herring R, et al. High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: planned week 12 interim analysis from the PROPEL study. Hepatology 2010; 52 Suppl 1:360A.
49. Pockros P, Jensen D, Tsai N, et al. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial. J Hepatol 2011; 54 Suppl 1:S538.
50. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376:1467-1475.
51. Le Pogam S, Chhabra M, Yan J-M, et al. Low rate of viral load rebound observed among treatment-naive genotype 1 patients with chronic hepatitis C treated with danoprevir (RG7227) plus PEG-IFN alfa-2a (40KD) (PEGASYS) plus ribavirin: interim analysis. Hepatology 2010; 52 Suppl 1:703A-704A.
52. Le Pogam S, Seshaaddri A, Kosaka A, et al. No evidence of drug resistance after up to 4 weeks treatment of GT 1, 2 and 3 hepatitis C virus infected individuals. J Hepatol 2009; 50 Suppl 1:S348.
53. Le Pogam S, Seshaadri A, Ewing A, et al. RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J Infect Dis 2010; 202:1510-1519.
54. Margeridon S, Le Pogam S, Liu T, et al. Ultra-deep sequencing of the NS3 and NS5B regions detects preexisting resistant variants to direct acting antivirals (DAA) in HCV genotype 1 treatment-naive infected patients. Hepatology 2010; 52 Suppl 1:714A.
55. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48:1769-1778.
56. Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009; 49:1069-1082.
57. Treviño A, de Mendoza C, Parra P, et al. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. Antivir Ther 2011; 16:413-416.
58. Le Pogam S, Yan J-M, Kosaka A, et al. No evidence of drug resistance or baseline S282T resistance mutation among GT1 and GT4 HCV-infected patients on nucleoside polymerase inhibitor RG7128 and PEG-IFN/RBV combination treatment for up to 12 weeks: interim analysis from the PROPEL study. Hepatology 2010; 52 Suppl 1:701A-702A.
59. Clinicaltrials.gov. A study on the combination of RO5024048 and ritonavir-boosted danoprevir with and without Copegus (ribavirin) in interferon-naive patients with chronic hepatitis C genotype 1 (INFORM-SVR). Clinicaltrials.gov NCT01278134. (Accessed 27 July 2011.) Available from http://clinicaltrials.gov/ct2/show/NCT01278134?term=danoprevir&rank=3
60. Clinicaltrials.gov. A study of danoprevir/ritonavir and Copegus with RO5024048 and/or Pegasys in patients with chronic hepatitis C. Clinicaltrials.gov NCT01331850. (Accessed 31 July 2011.) Available from http://clinicaltrials.gov/ct2/show/NCT01331850?term=RO5024048&rank=2
61. Sarrazin C, Lim S, Qi X, et al. Kinetic analysis of viral rebound and drug-resistant viral variant dynamics in patients treated with ITMN-191 (RG7227) monotherapy suggests a high barrier to viral escape. Hepatology 2009; 50 Suppl 1:953A.
62. Schlütter J. Therapeutics: new drugs hit the target. Nature 2011; 474:S5-7.